# A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Source: https://onco.cc/trials/nct07023731/  
OnCo record `nct07023731` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ARV-806 in advanced solid tumours, run by Arvinas Inc., active and no longer recruiting.

## Summary

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07023731 by Arvinas Inc., with 76 participants enrolled, started 2025-05-29 and due to reach its primary completion in 2026-11-30. Interventions recorded: ARV-806.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07023731
- Phase: 1/2
- Setting: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
- Sponsor: Arvinas Inc.
- Enrolled: 76

## Sources

- ClinicalTrials.gov NCT07023731: https://clinicaltrials.gov/study/NCT07023731

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Arvinas](https://onco.cc/companies/arvinas/)

---
JSON: https://onco.cc/api/v1/entities/nct07023731.json